Author:
Lin Kong-Ying,Chen Qing-Jing,Tang Shi-Chuan,Lin Zhi-Wen,Zhang Jian-Xi,Zheng Si-Ming,Li Yun-Tong,Wang Xian-Ming,Lu Qiang,Fu Jun,Guo Luo-Bin,Zheng Li-Fang,You Peng-Hui,Wu Meng-Meng,Lin Ke-Can,Zhou Wei-Ping,Yang Tian,Zeng Yong-Yi
Abstract
Abstract
Background
Routine clinical staging for hepatocellular carcinoma (HCC) incorporates liver function, general health, and tumor morphology. Further refinement of prognostic assessments and treatment decisions may benefit from the inclusion of tumor biological marker alpha-fetoprotein (AFP) and systemic inflammation indicator C-reactive protein (CRP).
Methods
Data from a multicenter cohort of 2770 HCC patients undergoing hepatectomy were analyzed. We developed the PACE risk score (Prognostic implications of AFP and CRP Elevation) after initially assessing preoperative AFP and CRP’s prognostic value. Subgroup analyzes were performed in BCLC cohorts A and B using multivariable Cox analysis to evaluate the prognostic stratification ability of the PACE risk score and its complementary utility for BCLC staging.
Results
Preoperative AFP ≥ 400ng/mL and CRP ≥ 10 mg/L emerged as independent predictors of poorer prognosis in HCC patients who underwent hepatectomy, leading to the creation of the PACE risk score. PACE risk score stratified patients into low, intermediate, and high-risk groups with cumulative 5-year overall (OS) and recurrence-free survival (RFS) rates of 59.6%/44.9%, 43.9%/38.4%, and 20.6%/18.0% respectively (all P < 0.001). Increased PACE risk scores correlated significantly with early recurrence and extrahepatic metastases frequency (all P < 0.001). The multivariable analysis identified intermediate and high-risk PACE scores as independently correlating with poor postoperative OS and RFS. Furthermore, the PACE risk score proficiently stratified the prognosis of BCLC stages A and B patients, with multivariable analyses demonstrating it as an independent prognostic determinant for both stages.
Conclusion
The PACE risk score serves as an effective tool for postoperative risk stratification, potentially supplementing the BCLC staging system.
Funder
Fujian Medical University Qihang Fund Graduate Innovation Project
National Natural Science Foundation of China
Science and Technology Innovation Joint Foundation of Fujian Province
Major Research Projects for Young and Middle-aged Researchers of Fujian Provincial Health Care Commission
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献